Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Amir London, CEO of Kamada, a major biopharmaceutical company that has a therapy for alpha-1 antitrypsin deficiency (AATD) approved by the US Food and Drug Administration and is now pursuing an inhaled alpha-1 antitrypsin (AAT) drug for the same disease.

Read the full story: Inhaled Therapy Could Transform AATD Treatment Landscape